Calidi Biotherapeutics' Warrants Under Review by NYSE
Calidi Biotherapeutics, Inc. (NYSE American: CLDI) has recently found itself in a critical position regarding its financial instruments. The NYSE Regulation team has resolved to initiate actions for the delisting of the company’s warrants, known by the ticker CLDI WS. This decision stems from a determination that the warrants are no longer appropriate for listing, largely due to the significant decline in their trading price.
Immediate Suspension of Trading
Effective immediately, trading of the company's warrants will cease. However, investors can take solace in knowing that the trading of the company’s common stock under the symbol CLDI will persist on the NYSE American platform. This segregation between the warrants and the common stock indicates an effort to maintain investor confidence while addressing underlying issues concerning the warrants.
Company's Right to Appeal Delisting Decision
Calidi Biotherapeutics retains the right to contest the NYSE Regulation's decision. The company can request a review from the Listings Qualifications Panel, which consists of a committee devoted to such matters. The outcome of this review process will play a significant role in determining the future of CLDI WS warrants. Meanwhile, the NYSE American is poised to submit a formal request to the Securities and Exchange Commission to proceed with the delisting, once all necessary procedures are fulfilled.
Understanding Calidi Biotherapeutics
Calidi Biotherapeutics is a pioneering player in the field of biotherapy, focusing on innovative solutions designed to combat various forms of cancer. The company's specialized approach combines immunology and innovative biology through its proprietary technology that harnesses the immune system's power to destroy cancer cells effectively. Their sophisticated stem cell-driven platforms are engineered to transport oncolytic viruses directly to the tumor site, providing promising therapeutic options.
Innovative Therapeutic Strategies
At the core of Calidi's research are the allogeneic stem cells that serve as carriers for oncolytic viruses. These viruses are specially developed to target specific oncology conditions, including aggressive high-grade gliomas and a range of solid tumors. By leveraging these advanced virotherapies, the company aspires to enhance the efficacy of cancer treatments while simultaneously improving patient safety outcomes.
Promising Applications in Oncology
Calidi Biotherapeutics is committed to a dual-therapeutic approach that aims not only to treat existing tumors but also to potentially prevent metastatic disease. Their preclinical efforts are geared toward the development of off-the-shelf solutions that promise to significantly alter the landscape of cancer treatment. The advancement of their clinical programs underscores a commitment to addressing unmet medical needs in oncology.
Looking Ahead for Calidi Biotherapeutics
As Calidi navigates the complexities introduced by this delisting alert, it remains focused on its key milestones, including the advancement of its clinical trials and ongoing research initiatives. The organization stands resolute in overcoming current challenges while continuing its quest to deliver innovative therapies designed to provide hope to patients battling cancer.
Key Contacts for Inquiries
For those interested in learning more about Calidi Biotherapeutics and its groundbreaking work in immunotherapy, direct inquiries can be sent to their investor relations representative. Stephen Thesing is available for media and investor questions via email at ir@calidibio.com.
Frequently Asked Questions
What led to the delisting of Calidi's warrants?
The NYSE Regulation team's decision was driven by the warrants' low trading prices, which deemed them unsuitable for continued listing.
Will Calidi's common stock continue trading?
Yes, Calidi's common stock, traded under the ticker CLDI, will continue on the NYSE American despite the suspension of its warrants.
Can Calidi contest the delisting decision?
Yes, Calidi has the right to appeal the delisting decision by requesting a review from the Listings Qualifications Panel.
What is Calidi Biotherapeutics focused on?
Calidi is focused on developing targeted antitumor virotherapies using innovative technologies designed to enhance cancer treatment efficacy.
How can investors contact Calidi for more information?
Investors can reach out to Stephen Thesing via email at ir@calidibio.com for further questions.
